Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 4, 2010, Pages 389-394

  Waldum, Helge L ^a,b   Qvigstad, Gunnar ^a,b   Fossmark, Reidar ^a,b   Kleveland, Per M ^a,b   Sandvik, Arne K ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Acid secretion; Enterochromaffin like cell; Gastrin; Histamine 2 blockers; Peptic ulcer disease; Proton pump inhibitors

Indexed keywords

ACETYLCHOLINE; AMINOPHENAZONE; GASTRIN; HISTAMINE; HISTAMINE H2 RECEPTOR AGONIST; HISTIDINE DECARBOXYLASE; OMEPRAZOLE; PENTAGASTRIN; PROTON PUMP INHIBITOR;

CLINICAL ASSESSMENT; DUODENUM ULCER; DYSPEPSIA; ENTEROCHROMAFFIN LIKE CELL; GASTRIN RELEASE; GASTRINOMA; GASTROESOPHAGEAL REFLUX; GLUCOSE CLAMP TECHNIQUE; HELICOBACTER INFECTION; HISTAMINE RELEASE; HUMAN; HYPERGASTRINEMIA; INNER CELL MASS; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH ANTRUM; STOMACH PARIETAL CELL; VAGUS NERVE STIMULATION;

ANIMALS; DYSPEPSIA; ENTEROCHROMAFFIN-LIKE CELLS; GASTRIC ACID; GASTRINOMA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE; HISTAMINE H2 ANTAGONISTS; HUMANS; PARIETAL CELLS, GASTRIC; PROTON PUMP INHIBITORS; RATS; STOMACH NEOPLASMS;

EID: 77949910670     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903477348     Document Type: Review

References (74)

1. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80-87
2. McColl KEL, Gillen D. Evidence that proton-pump inhibitor therapy induces symptoms it is used to treat. Gastroenterology 2009;137:20-22
3. News (Alisa Opar). A close look at acid reflux drugs points to possible risks. Nature Medicine 2009;15:710.
4. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649-653
5. Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf 2002;1:29-38.
6. Qvigstad G, Waldum HL. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol 2004;94:202-208
7. Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrinhistamine sequence in the regulation of gastric secretion. Gut 1991;32:698-701.
8. Håkanson R, Owman C. Concomitant histochemical demonstration of histamine and catecholamines in enterochromaffinlike cells of gastric mucosa. Life Sci 1967;6:759-766
9. Kahlson G, Rosengren E, Svahn D, Thunberg R. Mobilization and formation of histamine in the gastric mucosa as related to acid secretion. J Physiol 1964;174:400-416
10. Rangachari PK. Histamine release by gastric stimulants. Nature 1975;253:53-54
11. Kleveland PM, Waldum HL, Larsson M. Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion. Scand J Gastroenterol 1987;22:705-713
12. Sandvik AK, Waldum HL, Kleveland PM, Søgnen BS. Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol 1987;22:803-808
13. Waldum HL, Sandvik AK. Histamine and the stomach. Scand J Gastroenterol 1989;24:130-139
14. Brenna E, Waldum HL. Studies of isolated parietal and enterochromaffin-like cells from the rat. Scand J Gastroenterol 1991;26:1295-1306
15. Athmann C, Zeng N, Scott DR, Sachs G. Regulation of parietal cell calcium signaling in gastric glands. Am J Physiol 2000, 279:G1048-58.
16. Soll AH. Secretagogue stimulation of (14C)aminopyrine accumulation by isolated canine parietal cells. Am J Physiol 1980;238:G366-75.
17. Waldum HL, Sandvik AK, Brenna E. Gastrin: Histaminereleasing activity. p 259-271 In: Gastrin. JH. Walsh (editor), Raven Press, New York, 1993.
18. Bakke I, Qvigstad G, Sandvik AK, Waldum HL. The CCK-2 receptor is located on the ECL cell, but not on the parietal cell. Scand J Gastroenterol 2001;36:1128-1133
19. Blair AJ, Richardson JH, Walsh JH, Feldman M. Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology 1987;92:944-949
20. Waldum HL, Sandvik AK, Syversen U, Brenna E. The enterochromaffin-like (ECL) cell. Physiological and patophysiological role. Acta Oncologica 1993;32:141-147
21. Stempien SJ. Insulin gastric analysis: Technique and interpretation. Am J Dig Dis 1962;7:138-152
22. Kay, AW. Effect of large doses of histamine on gastric secretion of HCl. Br M J 1953;II:77-80.
23. Wormsley K, Grossman MI.Maximal histalog test in control subjects and patients with peptic ulcer. Gut 1965;6:427-435
24. Makhlouf GM, McManus JP, Card WI. Action of the pentapeptide (ICI 50123) on gastric secretion in man. Gastroenetrology 1966;51:455-465
25. Emås S, Grossman MI. Effect of truncal vagotomy on acid and pepsin responses to histamine and gastrin in cats. Am J Physiol 1969;213:657-662
26. A multicenter pilot studyPentagastrin as a stimulant of maximal gastric acid response in man. Lancet 1967;I:292-295
27. Qvigstad G, Bjørgaas M, Eide I, Sandvik AK, Waldum HL. Vagal stimulation augments maximal (penta) gastrin stimulated acid secretion in man. Acta Physiol Scand 1999;166:277-281
28. Kirsner JB, Ford H. The gastric secretory response to histalog: One-hour basal and histalog secretion in normal persons and in patients with duodenal ulcer and gastric ulcer. J Lab Clin Med 1955;46:307-311
29. Waldum HL, Brenna E. Sandvik AK. Maximal gastric acid secretion in man: A concept that needs precision. Scand J Gastroenterol 1998;33:1009-1015
30. Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Scherer S, et al.. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004;428:493-521.
31. Waldum HL, Lehy T, Brenna E, Sandvik AK, Petersen H, Søgnen BS, et al.. Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastric mucosa. Scand J Gastroenterol 1991;26:23-35.
32. Ryberg B, Tielemans Y, Axelson J, Carlsson E, Håkanson R, Mattson H, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990;99:935-942
33. Larsson H, Carlsson E, Ryberg B, Fryklund J, Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol 1988;254:G33-9.
34. Eriksson B, Öberg K, Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 1989;28:373-377
35. Bakke I, Qvigstad G, Brenna E, Sandvik AK, Waldum HL. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand 2000;169:29-37.
36. Crean GP, Marshall MW, Rumsey RDE. Parietal cell hyperplasia induced by the administration of pentagastrin (ICI 50,123) to rats. Gastroenterology 1969;57:147-156
37. Willems G, Vansteenkiste Y, Limbosch JM. Stimulating effect of gastrin on cell proliferation kinetics in canine fundic mucosa. Gastroenterology 1972;62:583-589.
38. Waldum HL, Brenna E, Sandvik AK. Relationship of ECL cells and gastric neoplasia. Yale J Biol Med 1998;71:325-335
39. Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Gardner JD, et al.. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992;102:767-778
40. Tielemans Y, Willems G, Sundler F, Håkanson R. Selfreplication of enterochromaffin-like cells in the mouse stomach. Digestion 1990;45:138-146
41. Magami Y, Azuma T, Inokuchi H, Moriyasu F, Kawai K, Hattori T. Cell kinetics of slow renewing cell populations in mice stomach. J Gastroenterol Hepatol 2002;17:262-269
42. Isenberg JI, Grossman MI, Maxwell V, Walsh JH. Increased sensitivity to stimulation of acid secretion by pentagastrin in duodenal ulcer. J Clin Invest 1975;55:330-337
43. Petersen H, Myren J. Pentgastrin dose-response in peptic ulcer disease. Scand J Gastroenterol 1975;10:705-714
44. Bodemar G, Walan ACimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet 1976;II:161-164
45. Bodemar G, Walan A, Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1978;I:403-407
46. Fiddian-Green RG, Bank S, Marks IN, Louw JH. Maximum acid output and risk of peptic ulcer. Lancet 1976, II, 1367-1369
47. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-1442
48. Levi S, Beardshall K, Haddad G, Playford R, Ghosh P, Calam JCampylobacter pylori and duodenal ulcer: the gastrin link. Lancet 1989;I, 1167-1168
49. Marshall BJ, Barrett LJ, Prakash C, McCallum RW, Guerrant RL. Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 1990;99:697-702.
50. Sandvik AK, Waldum HL. Rat gastric histamine release: A sensitive gastrin bioassay. Life Sciences 1990;46:453-459
51. Frislid K, Aadland E, Berstad A. Augmented postprandial gastric acid secretion due to exposure to ranitidine in healthy subjects. Scand J Gastroenterol 1986;21:119-122
52. Nwokolo CU, Smith JT, Sawyerr AM, Pounder RE. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut 1991;32:1455-1460.
53. Gillen D, Wirz AA, Ardill JE, McColl KEL. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239-247
54. Sandvik AK, Dimaline R, Mårvik R, Brenna E, Waldum HL. Gastrin regulates histidine decarboxylase activity and mRNA abundance in rat oxyntic mucosa. Am J Physiol 1994;267: G254-8.
55. Nwokolo CU, Prewett EJ, Sawyerr AFM, Hudson M, Lim S, Pounder RE. Tolerance during 5 months of dosing with ranitidine, 150 mg nightly;a placebo-controlled, double-blind study. Gastroenterology 1991;101:948-953
56. Lind T, Cederberg C, Forsell H, Olausson M, Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988;23:1259-1266
57. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005;21:149-154
58. Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004;126:980-988.
59. Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cell of the rat stomach: Establishment of a dose response relationship. Gut 1992;33:1303-1306.
60. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic astric acid hyposecretion. Gastroenterology 1997;113:15-24.
61. Kuipers EJ, Uyterlide AM, Peña AS, Hazenberg HJ, Bloemena E, Lindeman J, et al. Increase in Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995;90:1401-1406
62. Marshall BJ. Campylobacter pylori: Its link to gastritis and peptic ulcer disease. Rev Infect Dis. 1990;12(Supp 1)S87-93.
63. Saeed ZA, Evans DJ, Evans DG, Cornelius MJ, Maton PN, Jensen RT, et al. Helicobacter pylori and Zollinger-Ellison syndrome. Dig Dis Sci 1991;36:15-18.
64. Miller LS, Vinayek R, Frucht H, Gardner JD, Jensen RT, Maton PN. Reflux esophagitis in patients with Zollinger- Ellison syndrome. Gastroenterology 1990;98:341-346
65. Csendes A, øster M, Møller JT, Flynn J, Funch-Jensen P, Overgaard H, et al. Gastroesophageal reflux in duodenal ulcer patients before and after vagotomy. Ann Surg 1978;188:804-808
66. Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, Patel GK, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. New Engl J Med 1982;307:1547-1552
67. Loffeld RJLF, van der Putten ABMM. Rising incidence of reflux oesophagitis in patients undergoing upper gastrointestinal endoscopy. Digestion 2003;68:141-144
68. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P, et al. Heartburn treatment in primary care: randomized, double blind study for 8 weeks. BMJ 1999, 319:550-553
69. Viljakka M, Luostarinen M, Isolauri J. Incidence of antireflux surgery in Finland 1988-1993. Influence of proton-pump inhibitors and laparascopic technique. Scand J Gastroenterol 1997;32:415-418
70. Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double- blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;24:945-954
71. Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000;14:15-22.
72. Robinsen M, Decktor DL, Stone RC, Pevelery M, Barden P, Moyer R, et al. Famotidine (20mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive esophagitis. Aliment Pharmacol Ther 1991;5:631-643
73. Tytgat GNJAssessment of the efficacy of cimetidine and other drugs in oesophageal reflux disease. In: Cimetidine in the 80s. JH Baraon (editor). New York: Churchill Livingstone; 1981, p.153-166
74. Qvigstad G, Arnestad JS, Brenna E, Waldum HL. Treatment with proton pump inhibitors induces tolerance to histamine 2 receptor antagonists in Helicobacter pylori negative patients. Scand J Gastroenterol 1998;33:1244-1248